Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.42 |
| ▸ | JAK2 | O60674 | 19/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23070559 | 1.00 | NTRK1 (0.42) | NTRK1JAK2JAK1 | |
| SCHEMBL28370976 | 1.00 | NTRK1 (0.42) | NTRK1JAK2JAK1 | |
| SCHEMBL22151268 | 0.86 | NTRK1 (0.42) | NTRK1JAK2JAK1 | |
| SCHEMBL22151270 | 0.86 | NTRK1 (0.42) | NTRK1JAK2JAK1 | |
| SCHEMBL29977602 | 0.86 | NTRK1 (0.41) | NTRK1JAK2JAK1 | |
| SCHEMBL23070561 | 0.86 | NTRK1 (0.41) | NTRK1JAK2JAK1 | |
| SCHEMBL29978001 | 0.86 | NTRK1 (0.41) | NTRK1JAK2JAK1 | |
| SCHEMBL18555606 | 0.86 | NTRK1 (0.36) | NTRK1JAK2 | |
| SCHEMBL18555607 | 0.86 | NTRK1 (0.36) | NTRK1JAK2 | |
| SCHEMBL2598799 | 0.83 | NTRK1 (0.50) | NTRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822276-B1 | HETEROCYCLIC COMPOUND AS TRK INHIBITOR | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-11878987-B2 | Heterocyclic compound as TRK inhibitor | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-01-23 | — | — | US | disclosed |
| EP-3674307-B1 | MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| CN-111918868-B | Diaryl macrocycles as protein kinase modulators | 正大天晴药业集团股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878987-B2 | Heterocyclic compound as TRK inhibitor | NADK, NTRK3, TNNI3K | NTRK1 8/4885JAK2 983/4885JAK1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.